Dr. Robert C. Cartwright, MD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Georgia School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 277
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Medical College of Georgia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
GA license 052541
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Piedmont Columbus Regional Midtown Columbus, GA
Medical groups
- The Allergy Center at Brookstone PC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 277
- Services billed
- 17,324
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 2,593 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 215 | 159 |
| Professional service for multiple injections of allergen | 192 | 14 |
| Professional service for single injection of allergen | 187 | 11 |
| Professional service for preparation and provision of 1 or more antigens | 186 | 20 |
| Test to measure expiratory airflow and volume | 164 | 100 |
| Test to measure the level of nitric oxide gas | 148 | 91 |
| Established patient office or other outpatient visit, 20-29 minutes | 102 | 95 |
| New patient office or other outpatient visit, 45-59 minutes | 56 | 56 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluticasone Propionate Other prescribers in Columbus, GA | 284 |
| Montelukast Sodium Other prescribers in Columbus, GA | 254 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Columbus, GA | 155 |
| Ipratropium Bromide Other prescribers in Columbus, GA | 116 |
| Azelastine Hcl Other prescribers in Columbus, GA | 100 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Columbus, GA | 90 |
| Levocetirizine Dihydrochloride Other prescribers in Columbus, GA | 76 |
| Hydroxyzine Hcl Other prescribers in Columbus, GA | 46 |
| Epinephrine Other prescribers in Columbus, GA | 40 |
| Famotidine Other prescribers in Columbus, GA | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 99 payments worth $2,546 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $619 |
|---|---|
| GlaxoSmithKline, LLC. | $332 |
| Regeneron Healthcare Solutions, Inc. | $320 |
| Genzyme Corporation | $297 |
| Biocryst US Sales Co., LLC | $207 |
| Novartis Pharmaceuticals Corporation | $172 |
| Csl Behring | $141 |
| Amgen Inc. | $106 |
| Food and Beverage | $2,538 |
|---|---|
| Education | $8.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Apr 10, 2025 | Education DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $8.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $154,793 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435 - A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
AstraZeneca UK Limited - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults w…
AstraZeneca Pharmaceuticals LP - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP - A twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults w…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.